7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160
United States
510 474 0170
https://www.protagonist-inc.com
Sector(s):
Industry:
Full Time Employees: 112
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 825.45k | N/A | 1957 |
Dr. Suneel K. Gupta Ph.D. | Chief Development Officer | 598.81k | N/A | 1959 |
Dr. Mark Smythe Ph.D. | Founder & VP Technology | N/A | N/A | 1965 |
Mr. Asif Ali | Executive VP & Chief Financial Officer | N/A | N/A | 1974 |
Mr. Mohammad Masjedizadeh Ph.D. | Executive VP & Chief Technical Officer | N/A | N/A | N/A |
Mr. Matthew M. Gosling | Executive VP & General Counsel | N/A | N/A | 1971 |
Ms. Carena Spivey | Head of HR & Senior VP of Human Resources | N/A | N/A | N/A |
Dr. Ashok Bhandari Ph.D. | Executive VP & Chief Drug Discovery and Preclinical Development Officer | N/A | N/A | 1964 |
Mr. Carter J. King | Executive Vice President of Business Development | N/A | N/A | 1971 |
Ms. Abha Bommireddi | Executive Vice President of Portfolio & Program Management | N/A | N/A | N/A |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 7; Compensation: 8.